One of the immediate eukaryotic cellular responses to DNA breakage is the c
ovalent post-translational modification of nuclear proteins with poly(ADP-r
ibose) from NAD(+) as precursor, mostly catalysed by poly(ADP-ribose) polym
erase-1 (PARP-1). Recently several other polypeptides have been shown to ca
talyse poly(ADP-ribose) formation. Poly(ADP-ribosyl)ation is involved in a
variety of physiological and pathophysiological phenomena. Physiological fu
nctions include its participation in DNA-base excision repair, DNA-damage s
ignalling, regulation of genomic stability, and regulation of transcription
and proteasomal function, supporting the previously observed correlation o
f cellular poly(ADP-ribosyl)ation capacity with mammalian life. The pathoph
ysiology effects are mediated through PARP-1 overactivity, which can cause
cell suicide by NAD(+) depletion. It is apparent that the latter effect und
erlies the pathogenesis of a wide range of disease states including type-1
diabetes, ischaemic infarcts in various organs, and septic or haemorrhagic
shock. Therefore pharmacological modulation of poly(ADP-ribosyl)ation may p
rove to be an exciting option for various highly prevalent, disabling and e
ven lethal diseases. (C) 2001 John Wiley & Sons, Inc.